LakeShore Biopharma Debt
| LSBCF Stock | 0.13 0.03 18.75% |
At this time, LakeShore Biopharma's Net Debt is most likely to increase significantly in the upcoming years. The LakeShore Biopharma's current Interest Debt Per Share is estimated to increase to 6.58, while Short and Long Term Debt Total is projected to decrease to roughly 382.1 M. LakeShore Biopharma's financial risk is the risk to LakeShore Biopharma stockholders that is caused by an increase in debt.
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.35 | Current Value 0.33 | Quarterly Volatility 100.54035166 |
LakeShore | Build AI portfolio with LakeShore Stock |
LakeShore Biopharma Bond Ratings
LakeShore Biopharma Co financial ratings play a critical role in determining how much LakeShore Biopharma have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for LakeShore Biopharma's borrowing costs.| Piotroski F Score | 2 | Frail | View |
| Beneish M Score | (3.10) | Unlikely Manipulator | View |
LakeShore Biopharma Total Assets Over Time
LakeShore Biopharma Assets Financed by Debt
The debt-to-assets ratio shows the degree to which LakeShore Biopharma uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.LakeShore Biopharma Debt Ratio | 33.0 |
LakeShore Biopharma Corporate Bonds Issued
Most LakeShore bonds can be classified according to their maturity, which is the date when LakeShore Biopharma Co has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
LakeShore Short Long Term Debt Total
Short Long Term Debt Total |
|
Understaning LakeShore Biopharma Use of Financial Leverage
LakeShore Biopharma's financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures LakeShore Biopharma's total debt position, including all outstanding debt obligations, and compares it with LakeShore Biopharma's equity. Financial leverage can amplify the potential profits to LakeShore Biopharma's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if LakeShore Biopharma is unable to cover its debt costs.
| Last Reported | Projected for Next Year | ||
| Short and Long Term Debt Total | 476.6 M | 382.1 M | |
| Net Debt | 444.3 M | 466.5 M | |
| Short Term Debt | 449.5 M | 227.3 M | |
| Long Term Debt | 21.2 M | 20.1 M | |
| Short and Long Term Debt | 449 M | 279 M | |
| Net Debt To EBITDA | (9.15) | (8.70) | |
| Debt To Equity | 0.75 | 0.46 | |
| Interest Debt Per Share | 4.63 | 6.58 | |
| Debt To Assets | 0.35 | 0.33 | |
| Long Term Debt To Capitalization | 0.05 | 0.05 | |
| Total Debt To Capitalization | 0.41 | 0.26 | |
| Debt Equity Ratio | 0.75 | 0.46 | |
| Debt Ratio | 0.35 | 0.33 | |
| Cash Flow To Debt Ratio | (0.26) | (0.28) |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of LakeShore Biopharma Financial Statements. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Can Biotechnology industry sustain growth momentum? Does LakeShore have expansion opportunities? Factors like these will boost the valuation of LakeShore Biopharma. Expected growth trajectory for LakeShore significantly influences the price investors are willing to assign. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating LakeShore Biopharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Understanding LakeShore Biopharma requires distinguishing between market price and book value, where the latter reflects LakeShore's accounting equity. The concept of intrinsic value - what LakeShore Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push LakeShore Biopharma's price substantially above or below its fundamental value.
Understanding that LakeShore Biopharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether LakeShore Biopharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, LakeShore Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.